Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
Biomay, a biotech contract development and manufacturing organization based in Vienna, Austria, announces successful completion of an FDA inspection qualifying Biomay as a cGMP manufacturer and supplier of recombinant nuclease Cas9 for use in gene editing therapies.
Source: prleap.com